266 related articles for article (PubMed ID: 30869165)
1. Efficacy, safety, and tolerability of perampanel in Asian and non-Asian patients with epilepsy.
Tsai JJ; Ikeda A; Hong SB; Likasitwattanakul S; Dash A
Epilepsia; 2019 Mar; 60 Suppl 1():37-46. PubMed ID: 30869165
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of perampanel in generalized and focal to bilateral tonic-clonic seizures: A comparative study of Asian and non-Asian populations.
Nishida T; Lee SK; Wu T; Tiamkao S; Dash A
Epilepsia; 2019 Mar; 60 Suppl 1():47-59. PubMed ID: 30869168
[TBL] [Abstract][Full Text] [Related]
3. A post hoc analysis of the long-term safety and efficacy of perampanel in Asian patients with epilepsy.
Inoue Y; Kaneko S; Hsieh PF; Meshram C; Lee SA; Aziz ZA; Nabangchang C; Dash A
Epilepsia; 2019 Mar; 60 Suppl 1():60-67. PubMed ID: 30869167
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of adjunctive perampanel 4 mg/d for the treatment of focal seizures: A pooled post hoc analysis of four randomized, double-blind, phase III studies.
Steinhoff BJ; Patten A; Williams B; Malhotra M
Epilepsia; 2020 Feb; 61(2):278-286. PubMed ID: 31944276
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of adjunctive perampanel in patients with focal seizures or generalized tonic-clonic seizures: Post hoc analysis of Phase II and Phase III double-blind and open-label extension studies in India.
Mehndiratta MM; Gulhane M; Jabeen SA; Patten A; Dash A; Malhotra M
Epilepsia Open; 2021 Mar; 6(1):90-101. PubMed ID: 33681652
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, safety, and tolerability of adjunctive perampanel in patients from China with focal seizures or generalized tonic-clonic seizures: Post hoc analysis of phase III double-blind and open-label extension studies.
Weiping L; Dong Z; Zhen H; Patten A; Dash A; Malhotra M
CNS Neurosci Ther; 2021 Mar; 27(3):330-340. PubMed ID: 33340263
[TBL] [Abstract][Full Text] [Related]
7. Adjunctive perampanel in partial-onset seizures: Asia-Pacific, randomized phase III study.
Nishida T; Lee SK; Inoue Y; Saeki K; Ishikawa K; Kaneko S
Acta Neurol Scand; 2018 Apr; 137(4):392-399. PubMed ID: 29250772
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of perampanel in patients with drug-resistant partial seizures after conversion from double-blind placebo to open-label perampanel.
Montouris G; Yang H; Williams B; Zhou S; Laurenza A; Fain R
Epilepsy Res; 2015 Aug; 114():131-40. PubMed ID: 26088896
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of adjunctive perampanel in adolescent patients with epilepsy: Post hoc analysis of six randomized studies.
Piña-Garza JE; Rosenfeld W; Saeki K; Villanueva V; Yoshinaga H; Patten A; Williams B; Malhotra M
Epilepsy Behav; 2020 Mar; 104(Pt A):106876. PubMed ID: 31954998
[TBL] [Abstract][Full Text] [Related]
10. Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy A randomized trial.
French JA; Krauss GL; Wechsler RT; Wang XF; DiVentura B; Brandt C; Trinka E; O'Brien TJ; Laurenza A; Patten A; Bibbiani F
Neurology; 2015 Sep; 85(11):950-7. PubMed ID: 26296511
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the long-term efficacy and safety of adjunctive perampanel in tonic-clonic seizures: Analysis of four open-label extension studies.
Rektor I; Krauss GL; Inoue Y; Kaneko S; Williams B; Patten A; Malhotra M; Laurenza A; Wechsler RT
Epilepsia; 2020 Jul; 61(7):1491-1502. PubMed ID: 32645213
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of perampanel in adolescent patients with drug-resistant partial seizures in three double-blind, placebo-controlled, phase III randomized clinical studies and a combined extension study.
Rosenfeld W; Conry J; Lagae L; Rozentals G; Yang H; Fain R; Williams B; Kumar D; Zhu J; Laurenza A
Eur J Paediatr Neurol; 2015 Jul; 19(4):435-45. PubMed ID: 25823975
[TBL] [Abstract][Full Text] [Related]
13. Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307.
Krauss GL; Perucca E; Kwan P; Ben-Menachem E; Wang XF; Shih JJ; Patten A; Yang H; Williams B; Laurenza A
Epilepsia; 2018 Apr; 59(4):866-876. PubMed ID: 29574701
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of adjunctive Perampanel in a prospective, real-world, Phase IV study in Indian patients aged ≥12 years for Treatment of focal-onset Epilepsy: Study 508.
Ravat S; Rohatgi A; Kulkarni R; Jabeen SA; Patil B; Dash A; Malhotra M
Epilepsia Open; 2024 Jun; 9(3):940-950. PubMed ID: 38124551
[TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy and safety of adjunctive perampanel in patients from the Asia-Pacific region with refractory focal-onset seizures in Study 335 open-label extension.
Nishida T; Lee SK; Inoue Y; Saeki K; Ishikawa K; Malhotra M; Patten A; Kaneko S
Epilepsia Open; 2024 Apr; 9(2):501-512. PubMed ID: 37867420
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305.
French JA; Krauss GL; Steinhoff BJ; Squillacote D; Yang H; Kumar D; Laurenza A
Epilepsia; 2013 Jan; 54(1):117-25. PubMed ID: 22905857
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of perampanel in children and adults with various epilepsy syndromes: A single-center postmarketing study.
Singh K; Shah YD; Luciano D; Friedman D; Devinsky O; Kothare SV
Epilepsy Behav; 2016 Aug; 61():41-45. PubMed ID: 27300147
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies.
Steinhoff BJ; Ben-Menachem E; Ryvlin P; Shorvon S; Kramer L; Satlin A; Squillacote D; Yang H; Zhu J; Laurenza A
Epilepsia; 2013 Aug; 54(8):1481-9. PubMed ID: 23663001
[TBL] [Abstract][Full Text] [Related]
19. PERPRISE: A prospective non-interventional study of PERampanel as only adjunctive treatment in patients with PRImary or SEcondarily generalized tonic-clonic seizures: First interim analysis.
Steinhoff BJ; Goldmann T; Kockelmann E; Winter Y;
Epilepsia Open; 2024 Jun; 9(3):926-939. PubMed ID: 38017663
[TBL] [Abstract][Full Text] [Related]
20. Perampanel, an AMPA receptor antagonist: From clinical research to practice in clinical settings.
Tsai JJ; Wu T; Leung H; Desudchit T; Tiamkao S; Lim KS; Dash A
Acta Neurol Scand; 2018 Apr; 137(4):378-391. PubMed ID: 29214650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
